– Sec Filing
Samsung Biologics Reached Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis for Up to $2.3B
Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout of Biogen's stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis' growth outlook.
